^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    COM701

    i
    Other names: COM701, CGEN-15029, COM701/PVRIG, COM 701, COM-701, CGEN15029, CGEN 15029
    Company:
    Compugen
    Drug class:
    PVRIG inhibitor
    Related drugs:
    4ms
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=48, Completed, Compugen Ltd | Active, not recruiting --> Completed | N=100 --> 48
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    4ms
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=121, Completed, Compugen Ltd | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701
    9ms
    COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=110, Recruiting, Compugen Ltd | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • COM701 • COM902
    9ms
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    9ms
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Compugen Ltd | Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Feb 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701
    almost2years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    almost2years
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1a/1b, N=140, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701
    over2years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Compugen Ltd | Trial primary completion date: Aug 2022 --> Jan 2023
    Trial primary completion date • Combination therapy
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    3years
    COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839) (SITC 2021)
    Data cutoff 28 Jun 2021. Trial Registration NCT04570839
    Clinical • PK/PD data • Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    3years
    COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246). (SITC 2021)
    Enrollment into combination cohort (COM902 + COM701), for evaluation of safety/tolerability at the RDFE of both study drugs, combination dose expansion (COM902 + COM701) in pts with HNSCC, NSCLC and CRC-MSS and COM902 monotherapy dose expansion (pts with multiple myeloma) all at the RDFE of study drug(s) are planned. Data cut June 28, 2021. Trial Registration NCT04354246
    Clinical • PK/PD data
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    COM701 • COM902
    over3years
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1a/1b, N=140, Recruiting, Compugen Ltd | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jun 2021 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701
    over3years
    COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. (PubMed, Cancer Immunol Immunother)
    COM902, either alone or in combination with a PVRIG (COM701) or PD-1 inhibitor, enhances antigen-specific human T cell responses in-vitro. In-vivo, a mouse chimeric version of COM902 in combination with an anti-PVRIG or anti-PD-L1 antibody inhibited tumor growth and increased survival in two syngeneic mouse tumor models. In summary, COM902 enhances anti-tumor immune responses and is a promising candidate for the treatment of advanced malignancies.
    Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule)
    |
    CD8 expression
    |
    COM701 • COM902
    almost5years
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1a/1b, N=140, Recruiting, Compugen Ltd | Trial primary completion date: Jan 2020 --> Jun 2021
    Clinical • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701